A detailed history of Goldman Sachs Group Inc transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 179,005 shares of RGLS stock, worth $250,606. This represents 0.0% of its overall portfolio holdings.

Number of Shares
179,005
Previous 138,465 29.28%
Holding current value
$250,606
Previous $247,000 13.77%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.46 - $1.9 $59,188 - $77,026
40,540 Added 29.28%
179,005 $281,000
Q2 2024

Aug 13, 2024

SELL
$1.79 - $2.8 $159,227 - $249,071
-88,954 Reduced 39.11%
138,465 $247,000
Q1 2024

May 15, 2024

BUY
$1.13 - $2.88 $256,983 - $654,966
227,419 New
227,419 $654,000

Others Institutions Holding RGLS

About Regulus Therapeutics Inc.


  • Ticker RGLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,634,400
  • Market Cap $20.5M
  • Description
  • Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...
More about RGLS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.